Multiple Sclerosis (MS) is a chronic, progressive, degenerative disorder of the central nervous system (brain, spinal cord and optical nerve). MS is more common in females and onset usually occurs in young adults. It affects the Central Nervous System and people with MS may have problems with walking, talking, clumsiness, memory, cognitive functioning, visual disturbance and / or muscle weakness.
The BRAVO study (Benefit Risk Assessment of Avonex and Laquinimod) is an international clinical trial which aims to assess the safety and effectiveness of an oral medication for the treatment of Relapsing Remitting Multiple Sclerosis.
To be eligible for the study, you must:
Trials will be conducted in Jo'burg, Bloemfontein, Cape Town, Pretoria Pietermaritzburg, and Tygerberg.
If you are interested in participating or would like more information, contact: 0861 TRIALS (0861 874257) or sms TRIALS to 32010